SMAD2 and cancer: Their findings revealed the important role of the p-SMAD2/3 pathway in hepaCAM-induced apoptosis of cancer cells, and provided valuable insights for current and future clinical trials of Ad-hepaCAM and p-SMAD2/3 (Wang et al., 2016).